1 published article · Updated continuously
9 trials tracked for chemotherapy-induced neutropenia: 6 in phase 3 or 4 and 4 with published results. The most-cited published study has 37 citations.
Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical trials have evaluated several interventions for managing chemotherapy-induced neutropenia. LA-EP2006 was assessed in two Phase 3 trials, which reported mean durations of severe neutropenia (DSN) during Cycle 1 as 0.75 to 0.83 days 1 and 1.19 to 1.36 days 4. Correspondingly, the time to ANC recovery in Cycle 1 was recorded at 1.58 to 1.72 days 1 and 2.04 to 2.11 days 4.
Empegfilrastim (6 mg) was evaluated in a Phase 3 trial where the incidence of severe neutropenia (Grade 3-4) was recorded at 34, 40, and 40 across study arms 6. This trial also measured the duration of Grade 4 neutropenia; during Cycle 1, durations were reported as 0.791, 0.905, and 1.725 days 6, while from the 2nd to 4th cycle (Week 12), durations ranged from 0.244 to 0.925 days 6.
Other interventions evaluated in Phase 3 trials for this condition include Neugranin 3 and Balugrastim 5. Additionally, Plinabulin was assessed in a Phase 3 trial where results included changes in estimated mean bone pain scores of 1.69 and 2.35, and the proportion of patients with a neutrophil-to-lymphocyte ratio (NLR) > 5 was recorded as 2 and 24 2. Plinabulin was also evaluated in a Phase 2 trial 7.
AI synthesis of 9 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
